Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

Summary

Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Pulmonary Disease, Chronic Obstructive

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

40 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

GlaxoSmithKline

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites